Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors

Cancer Biology and Therapy

Volumn 5, Issue 1, 2006, Pages 22-27

  Dahut, William L ^a   Lakhani, Nehal J ^a,b   Gulley, James L ^a   Arlen, Philip M ^a   Kohn, Elise C ^a   Kotz, Herbert ^a   McNally, Debbie ^a   Pair, Allyson ^a   Nguyen, Diana ^a   Yang, Sherry X ^a   Steinberg, Seth M ^a   Venitz, Jürgen ^b   Sparreboom, Alex ^a,b   Figg, William D ^a,b,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c Building 10 ^*  (United States)

Author keywords

2 methoxyestradiol (2ME2); Angiogenesis; Apoptosis; Clinical trial; Phase I; Solid tumor

Indexed keywords

2 METHOXYESTRADIOL; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; CD31 ANTIGEN; CHOLESTEROL; DIPHENHYDRAMINE; ENALAPRIL; GLUCOSE; KI 67 ANTIGEN; MAGNESIUM; SODIUM CHLORIDE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADRENAL CORTEX CARCINOMA; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLERGIC REACTION; ALOPECIA; ANEMIA; ANGIONEUROTIC EDEMA; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BLOOD SAMPLING; BLOOD TOXICITY; BONE MARROW TOXICITY; BREAST ADENOCARCINOMA; CANCER PATIENT; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CARCINOMA; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRY SKIN; EMBOLISM; FATIGUE; FEMALE; HEADACHE; HEART ARRHYTHMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERMAGNESEMIA; HYPOALBUMINEMIA; HYPOMAGNESEMIA; HYPONATREMIA; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LETHARGY; MALAISE; MALE; MALE INFERTILITY; MAXIMUM TOLERATED DOSE; MEDICAL ASSESSMENT; MELANOMA; MICROVASCULATURE; NAUSEA; OVARY CARCINOMA; PAIN; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMOTHORAX; PROSTATE ADENOCARCINOMA; PROTEINURIA; RECTUM CARCINOMA; RESPIRATORY FAILURE; SARCOMA; SENSORY NEUROPATHY; SINUS TACHYCARDIA; SKIN EXFOLIATION; SOLID TUMOR; TANDEM MASS SPECTROMETRY; THROMBOSIS; TISSUE SECTION; TUMOR BIOPSY; VAGINA BLEEDING;

EID: 32544433479     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.1.2349     Document Type: Article

References (32)

1. Berg FD, Kuss E. Serum concentration and urinary excretion of 'classical' estrogens, catecholestrogens and 2-methoxyestrogens in normal human pregnancy. Arch Gynecol Obstet 1992; 251:17-27.
2. Schumacher G, Kataoka M, Roth JA, et al. Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines. Clin Cancer Res 1999; 5:493-9.
3. Fotsis T, Zhang Y, Pepper MS, et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994; 368:237-9.
4. Klauber N, Parangi S, Flynn E, et al. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997; 57:81-6.
5. Wassberg E. Angiostatic treatment of neuroblastoma. Ups J Med Sci 1999; 104:1-24.
6. Seegers JC, Lottering ML, Grobler CJ, et al. The mammalian metabolite, 2-methoxyestradiol, affects P53 levels and apoptosis induction in transformed cells but not in normal cells. J Steroid Biochem Mol Biol 1997; 62:253-67.
7. Zacharia LC, Jackson EK, Gillespie DG, et al. Increased 2-methoxyestradiol production in human coronary versus aortic vascular cells. Hypertension 2001; 37:658-62.
8. D'Amato RJ, Lin CM, Flynn E, et al. 2-methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci USA 1994; 91:3964-8.
9. Mabjeesh NJ, Escuin D, La Valee TM, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003; 3:363-75.
10. Lakhani NJ, Lepper ER, Sparreboom A, et al. Determination of 2-methoxyestradiol in human plasma, using liquid chromatography-tandem mass spectrometry. Rapid Comm Mass Spec 2005; 19:1176-82.
11. Tan AR, Yang X, Hewitt SM, et al. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol 2004; 22:3080-90.
12. Hollander M, Wolfe DA. Nonparametric statistical methods. 2nd ed. John Wiley and Sons Inc., 1999:189-269.
13. Tsuda H, Bandera CA, Birrer MJ, et al. Cyclin E amplification and overexpression in clear cell adenocarcinoma of the ovary. Oncology 2004; 67:291-9.
14. Yamamoto S, Konishi I, Mandai M, et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: Correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 1997; 76:1221-7.
15. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359:843-5.
16. Goff BA, Sainz de la Cuesta R, Muntz HG, et al. Clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996; 60:412-7.
17. Behbakht K, Randall TC, Benjamin I, et al. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol 1998; 70:255-8.
18. Miller KD, Haney LG, Pribluda VS, et al. A phase I safety, pharmacokinetic and pharmacodynamic study of 2-methoxyestradiol (2ME2) in patients with refractory metastatic breast cancer. Proceedings of The American Society of Clinical Oncology 2001; 20:43a.
19. Wilding G, Sweeney C, King DM, et al. Phase 2, multicenter, randomized, double blind, safety, pharmacokinetic, pharmacodynamic and efficacy study of two doses of 2-methoxyestradiol administered orally in patients with hormone refractory prostate cancer [abstr]. Orlando: Proceedings of American Society of Clinical Oncology Presented at the 38th annual meeting of the American Society of Clinical Oncology, 2002, (2003).
20. Miller KD, Murry DJ, Curry E, et al. A phase I study of 2-methoxyestradiol (2ME2) plus docetaxel in patients with metastatic breast cancer. Proceedings of The American Society of Clinical Oncology 2002; 21:111a.
21. DeMario MD, Ratain MJ. Oral chemotherapy: Rationale and future directions. J Clin Oncol 1998; 16:2557-67.
22. Hellriegel ET, Bjornsson TD, Hauck WW. Interpatient variability in bioavailability is related to the extent of absorption: Implications for bioavailability and bioequivalence studies. Clin Pharmacol Ther 1996; 60:601-7.
23. Takahashi K, Okada M, Ozaki T, et al. Safety and efficacy of oestriol for symptoms of natural or surgically induced menopause. Hum Reprod 2000; 15:1028-36.
24. Biing JT, Yang YF, Liu HS, et al. The induction of multidrug resistance in human cervical carcinoma cell lines by estrogenic hormones. Proc Natl Sci Counc Repub China B 1994; 18:64-70.
25. Fujise H, Annoura T, Sasawatari S, et al. Transepithelial transport and cellular accumulation of steroid hormones and polychlorobiphenyl in porcine kidney cells expressed with human P-glycoprotein. Chemosphere 2002; 46:1505-11.
26. Maliepaard M, Scheffer GL, Faneyte IF, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001; 61:3458-64.
27. Kruijtzer CMF, Beijnen JH, Rosing H, et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and p-glycoprotein inhibitor GF120918. J Clin Oncol 2002; 20:2943-50.
28. Sugimoto Y, Tsukahara S, Imai Y, et al. Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. Mol CancerTher 2003; 2:105-112.
29. Imai Y, Tsukahara S, Ishikawa E, et al. Estrone and 17b-estradiol reverse breast cancer resistance protein-mediated multidrug resistance. Jpn J Cancer Res 2002; 93:231-235.
30. Ee RPL, Kamalakaran S, Beck WT. Regulation of human breast cancer resistance protein (BCRP/ABCG2) by estrogen. Proceedings of the American Association for Cancer Research 2003; 44:113.
31. Janvilisri T, Venter H, Shahi S, et al. Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem 2003; 20645-51.
32. Imai Y, Asada S, Tsukahara S, et al. Breast cancer resistance protein transports sulfated conjugates of estrone and 17b-estradiol. Proceedings of the American Association for Cancer Research, 2003:44:112.